The hemodynamics of erection and the pharmacotherapies of erectile dysfunction

Heart Disease

Volumn 4, Issue 4, 2002, Pages 252-264

  Melman, Arnold ^a   Christ, George J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLIC AMP; CYCLIC GMP; HYDRALAZINE; MILRINONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAPAVERINE; PHENOXYBENZAMINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; QUAZINONE; RESERPINE; ROLIPRAM; SILDENAFIL; TADALAFIL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; YOHIMBINE; ZAPRINAST;

ADULT; AGED; AUTONOMIC NERVOUS SYSTEM; BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOPPLER FLOWMETRY; DRUG EFFICACY; DRUG POTENCY; DYSPEPSIA; ERECTILE DYSFUNCTION; GENE THERAPY; HEADACHE; HEMODYNAMICS; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PENIS ERECTION; PLETHYSMOGRAPHY; RETINA DISEASE; REVIEW; RHINITIS; SYNCOPE;

EID: 0036637599     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200207000-00008     Document Type: Review

References (84)

1. The epidemiology of erectile dysfunction
2. Sexuality and aging
3. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study
4. Intracavernous self-injection pharmacotherapy program: Analysis of results and complications
5. Consensus development conference statement on impotence
6. Impotence
7. A review of erectile dysfunction: New insights and more questions
8. Physiology of erection and pharmacologic management of impotence
9. Physiology of penile erection
10. Pharmacotherapeutic advances in the treatment of erectile dysfunction
11. The penis as a vascular organ: The importance of corporal smooth muscle tone in the control of erection
12. Pharmacological studies of human erectile tissue: Characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues
13. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men
14. 1-adrenergic contractions in human corpus cavernosum smooth muscle
15. The relationship between contraction and relaxation in human corpus cavernosum smooth muscle
16. Characterization of nitroglycerine-induced relaxation in human corpus cavernosum smooth muscle: Implications to erectile physiology and dysfunction
17. Trabecular smooth muscle modulates the capacitor function of penis: Studies on a rabbit model
18. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence
19. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission
20. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum
21. Impotence
22. Erectile dysfunction associated with cavernous and neurological model
23. Pathophysiology of erectile dysfunction
24. Insufficient penile erection due to abnormal drainage of cavernous bodies
25. Female sexual dysfunction
26. Testosterone deficiency and supplementation for women
27. Penile revascularization
28. Interview of wives a necessary adjunct in the evaluation of impotence
29. Current status of arterial evaluation and revascularization for arteriogenic erectile dysfunction
30. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction
31. Intracavernous injection of papaverine for erectile failure
32. Nitric oxide in the penis: Physiology and pathology
33. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves
34. Integrative erectile biology: The effects of Age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction
35. Physiological roles for K+ channels and gap junctions in urogenital smooth muscle: Implications for improved understanding of urogenital function, disease and therapy
36. Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro
37. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil
38. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
39. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
40. Cyclic GMP phosphodiesterase-5: Target of sildenafil
41. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo
42. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction
43. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
44. Sildenafil, a novel effective oral therapy for male erectile dysfunction
45. Oral sildenafil in the treatment of erectile dysfunction
46. The international index of erectile function(I-IEF): A multidimensional scale for assessment of erectile dysfunction
47. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial
48. Oral drug therapy for erectile dysfunction
49. Sildenafil citrate: A therapeutic update
50. Some men who take Viagra die - Why?
51. Studies of Viagra offer some reassurance to men with concerns about cardiac effects
52. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England
53. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart
54. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device
55. Safe use of sildenafil in patients with coronary artery disease
56. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication
57. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy
58. The diffusion of a novel therapy into clinical practice: The case of sildenafil
59. Evaluation of the first 406 patients in Urology department based center for male sexual dysfunction
60. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg Apomorphine SL in male erectile dysfunction
61. Apomorphine: An update of clinical trial results
62. Recovery of erectile function by the oral administration of apomorphine
63. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
64. Cardiovascular effects of apomorphine in humans: Evidence for peripheral mechanisms
65. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates
66. Pharmacology of erectile function and dysfunction
67. Oral phentolamine in non-specific erectile insufficiency
68. Experience with buccal phentolamine mesylate for impotence
69. Buccal phentolamine: A pilot study for male erectile dysfunction at three separate clinics
70. Tamsulosin 0.4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
71. Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with melanotan II
72. Some proposals regarding the organization of the central nervous system control of penile erection
73. Intraurethral prostaglandin E-2 cream: A possible alternative treatment for erectile dysfunction
74. Treatment of men with erectile dysfunction with transurethral alprostadil
75. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - A comparative study in 103 patients with erectile dysfunction
76. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - A comparative study in 103 patients with erectile dysfunction
77. Cavernosal alpha-blockage: A new technique for investigating and treating erectile impotence
78. 1 for the treatment of erectile impotence
79. For the Alprostadil Study Group: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
80. Intracorporal injection of hSLO cDNA in rats produces physiologically relevant alteration in penile function
81. Cloning of rat and human inducible nitric oxide synthase. Application for gene therapy of erectile dysfunction
82. Impotence in medical clinic outpatients
83. The hemodynamics of erection and the pharmacotherapy of erectile dysfunction